Brokerages expect Natera Inc (NASDAQ:NTRA) to announce $66.23 million in sales for the current quarter, according to Zacks Investment Research. Three analysts have provided estimates for Natera’s earnings, with estimates ranging from $65.50 million to $67.25 million. Natera posted sales of $56.66 million during the same quarter last year, which would indicate a positive year over year growth rate of 16.9%. The firm is expected to report its next quarterly earnings report on Wednesday, November 14th.
According to Zacks, analysts expect that Natera will report full year sales of $262.85 million for the current financial year, with estimates ranging from $259.50 million to $266.00 million. For the next financial year, analysts expect that the firm will post sales of $328.14 million per share, with estimates ranging from $310.00 million to $340.32 million. Zacks’ sales calculations are an average based on a survey of analysts that follow Natera.
Natera (NASDAQ:NTRA) last posted its earnings results on Wednesday, August 8th. The medical research company reported ($0.55) EPS for the quarter, hitting the Zacks’ consensus estimate of ($0.55). The business had revenue of $63.07 million during the quarter, compared to analyst estimates of $61.71 million. Natera had a negative return on equity of 752.93% and a negative net margin of 59.07%. The company’s quarterly revenue was up 20.6% compared to the same quarter last year. During the same quarter last year, the company earned ($0.55) EPS.
NTRA has been the topic of a number of research reports. Morgan Stanley raised their price target on Natera from $16.00 to $20.00 and gave the stock an “overweight” rating in a research note on Monday, June 25th. Piper Jaffray Companies raised their price target on Natera to $27.00 and gave the stock an “overweight” rating in a research note on Thursday, August 9th. Robert W. Baird raised their price target on Natera from $17.00 to $20.00 and gave the stock an “outperform” rating in a research note on Thursday, June 28th. ValuEngine upgraded Natera from a “buy” rating to a “strong-buy” rating in a research note on Friday, June 22nd. Finally, Craig Hallum set a $23.00 price target on Natera and gave the stock a “positive” rating in a research note on Thursday, June 28th. Two equities research analysts have rated the stock with a hold rating, six have issued a buy rating and one has assigned a strong buy rating to the company. The company presently has a consensus rating of “Buy” and an average target price of $23.14.
NTRA stock opened at $25.39 on Friday. The firm has a market capitalization of $1.53 billion, a PE ratio of -10.58 and a beta of 2.21. Natera has a 1 year low of $8.60 and a 1 year high of $29.62. The company has a current ratio of 1.69, a quick ratio of 1.56 and a debt-to-equity ratio of -3.32.
In related news, COO Steven Leonard Chapman sold 86,919 shares of Natera stock in a transaction on Monday, June 25th. The stock was sold at an average price of $18.00, for a total transaction of $1,564,542.00. Following the transaction, the chief operating officer now directly owns 3,588 shares in the company, valued at $64,584. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, CEO Matthew Rabinowitz sold 403,462 shares of Natera stock in a transaction on Thursday, September 13th. The shares were sold at an average price of $24.90, for a total value of $10,046,203.80. Following the transaction, the chief executive officer now owns 1,701,686 shares in the company, valued at $42,371,981.40. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 748,061 shares of company stock worth $17,896,570. Company insiders own 13.18% of the company’s stock.
A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Sofinnova Ventures Inc purchased a new position in Natera during the first quarter valued at $28,742,000. Jennison Associates LLC lifted its position in Natera by 1.4% during the second quarter. Jennison Associates LLC now owns 2,617,623 shares of the medical research company’s stock valued at $49,264,000 after purchasing an additional 36,876 shares in the last quarter. BlackRock Inc. lifted its position in Natera by 19.4% during the second quarter. BlackRock Inc. now owns 2,086,829 shares of the medical research company’s stock valued at $39,274,000 after purchasing an additional 338,766 shares in the last quarter. Fred Alger Management Inc. purchased a new position in Natera during the second quarter valued at $33,271,000. Finally, Macquarie Group Ltd. lifted its position in Natera by 9.0% during the second quarter. Macquarie Group Ltd. now owns 1,714,886 shares of the medical research company’s stock valued at $32,274,000 after purchasing an additional 141,278 shares in the last quarter. Institutional investors own 66.31% of the company’s stock.
Natera Company Profile
Natera, Inc, a diagnostics company, provides preconception and prenatal genetic testing services. It primarily offers Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus typically with a blood draw from the mother; Vistara, a single-gene mutations screening test to identify single-gene disorder; Horizon carrier screening to determine carrier status for various genetic diseases that could be passed on to the carrier's children; and Spectrum pre-implantation genetic screening and Spectrum pre-implantation genetic diagnosis to analyze chromosomal anomalies or inherited genetic conditions during an in vitro fertilization cycle.
Recommended Story: Is the Dow Jones Industrial Average (DJIA) still relevant?
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Natera Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Natera and related companies with MarketBeat.com's FREE daily email newsletter.